Vilon
Also known as: KE peptide, Lys-Glu, KE dipeptide
Short peptide bioregulator / dipeptide (Lys-Glu)
What it is
Vilon is a synthetic dipeptide used in the longevity community for immune modulation and anti-aging effects. Research suggests it works by influencing gene expression in immune and skin cells to slow aging processes. No FDA-approved use; primarily studied in Russian longevity research with limited independent replication.
The scientific side
Vilon (Lys-Glu, KE dipeptide) is a synthetic dipeptide bioregulator originally characterized by Prof. Khavinson and described as having immunomodulatory, oncostatic, and geroprotective effects. According to molecular modeling data, the KE peptide can interact with specific dsDNA sequences (GCGG in classical B-form dsDNA and GGGC in curved dsDNA nucleosome), with these sequences found in the promoters of the SIRT1, PARP1, and PARP2 genes, suggesting a mechanism of direct gene expression regulation (PMID 37042594; PMID 37782636). Vilon has been shown to modulate chromatin structure, inducing deheterochromatinization of facultative heterochromatin in lymphocytes from aged individuals, and activating synthetic processes of ribosomal genes. It regulates expression of genes involved in aging (IGF1, FOXO1, TERT, TNKS2, NFκB) in human mesenchymal stem cells at nanomolar concentrations, and modulates SIRT1, PARP1, and PARP2 gene expression and protein synthesis during MSC aging. It increases mitochondrial staining and decreases ribosomal protein L7A expression in thymic cells, and increases collagen type I and sirtuin-6 expression in skin fibroblasts. In the immune system, Vilon and its analogues affect CD5, CD4+, and CD8+ T-cell differentiation in thymic cell cultures. In monocyte/macrophage cell lines, Vilon modulates inflammatory and proliferative processes, including inhibition of TNF and IL-6 cytokine production and reduction of cell adhesion to activated endothelial cells.
Class: Short peptide bioregulator / dipeptide (Lys-Glu)
Administration & storage
- Cautions
- No human pharmacokinetic data are reported in the reviewed abstracts for Vilon; all mechanistic studies identified were conducted in vitro.,No specific safety, tolerability, or adverse event data for Vilon are reported in the reviewed abstracts — safety profile in humans is not established from this literature.,Sterile technique is essential for any injectable peptide preparation to prevent contamination.,Regulatory status of Vilon for human use is not stated in the reviewed literature; use outside of approved clinical or research settings may carry unknown risks.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Geroprotection / anti-aging Mixed
- Review summarizing long-term clinical studies of peptide bioregulators including Vilon for prevention of diseases and treatment of people of different ages, with particular attention to their use as geroprotectors. PMID 24003726 Khavinson VKh et al. Advances in gerontology (2013)
- KE peptide at nanomolar concentrations modulated expression of IGF1, FOXO1, TERT, TNKS2, and NFκB genes in human mesenchymal stem cell aging cultures; KE increased FOXO1 expression ~2-fold in the stationary aging model and stimulated NFκB gene expression in both aging models. PMID 32399807 Ashapkin V et al. Molecular biology reports (2020)
- KE peptide increased SIRT1 gene expression and protein synthesis by 6 and 8.2 times respectively in young MSCs; reduced PARP1 and PARP2 gene expression and protein synthesis during MSC aging by 2.1- and 5.3-fold (PARP1) and 2.1- and 4.7-fold (PARP2). PMID 37782636 Khavinson VK et al. Advances in gerontology (2023)
- KE peptide increased MitoTracker Red mitochondrial staining by 1.5 times and decreased L7A ribosomal protein expression by 15% in cultures of human thymic cells during senescence, suggesting tissue-specific normalization of mitochondrial and ribosomal function. PMID 33342107 Ivko OM et al. Advances in gerontology (2020)
- Immunomodulation Mixed
- Vilon analogues (AB-O and R-1 dipeptides) increased CD5 expression in cultured human and rat thymic cells. Dipeptide R-1 stimulated differentiation of CD5+ cells to mature T-helpers and cytotoxic CD8+ T cells, suggesting immunomodulator and antiallergic activity. PMID 23486604 Sevostianova NN et al. Bulletin of experimental biology and medicine (2013)
- Vilon dipeptide modulated proliferative patterns (increasing tyrosine phosphorylation of mitogen-activated cytoplasmic kinases) and inhibited TNF and IL-6 cytokine expression stimulated by LPS in differentiated THP-1 cells; also reduced monocyte adhesion to LPS-activated endothelial cells. PMID 35408963 Avolio F et al. International journal of molecular sciences (2022)
- Epigenetic modification / chromatin remodeling in aging In vitro only
- KE (Lys-Glu / Vilon) induced deheterochromatinization of total heterochromatin and satellite stalks of acrocentric chromosomes, activating ribosomal gene synthetic processes in lymphocytes from individuals aged 75–88, without affecting pericentromeric structural heterochromatin. PMID 37042594 Lezhava T et al. Georgian medical news (2023)
- Skin aging / fibroblast function In vitro only
- KE dipeptide increased collagen type I expression area in 'old' skin fibroblast cultures by 83%, and increased sirtuin-6 expression in young and old fibroblasts by 1.6 and 2.6 times, respectively, suggesting promotion of functional activity and inhibition of aging in skin fibroblasts. PMID 29322736 Fridman NV et al. Advances in gerontology (2017)
- Neuronal differentiation of stem cells In vitro only
- A compound of peptides including KE (Lys-Glu) promoted neuronal differentiation of human periodontal ligament stem cells, with increased expression of GAP43 and Nestin, suggesting potential as a modulator of neurogenesis. PMID 30791821 Caputi S et al. International journal of immunopathology and pharmacology (2019)
- Regulation of CCL11 and HMGB1 gene expression (aging biomarkers) In vitro only
- Review proposing a role for Vilon (Lys-Glu) as an activator of CCL11 and HMGB1 gene expression, with geroprotective action potentially realized through suppression of these genes, based on analysis of short peptide DNA-binding interactions. PMID 25826983 Khavinson VKh et al. Advances in gerontology (2014)
- Dental disease / oral and maxillofacial pathology (bioregulatory therapy) Human observational
- Review reporting the use of peptide bioregulators including Vilon (as a thymomimetic) in the complex treatment of dental diseases in the elderly, with immunopharmacological effects described. PMID 32362097 Pinelis IS et al. Advances in gerontology (2020)
- Genome functional regulation in hypertrophic cardiomyopathy In vitro only
- Vilon was tested alongside Epithalon and Livagen on lymphocyte cultures from patients with hypertrophic cardiomyopathy (HCM) and their relatives. Different effects of the bioregulators were noted; Epithalon showed the most effective protective action in normalizing genome functional parameters. PMID 24423684 Dzhokhadze TA et al. Georgian medical news (2013)
Safety signals
- No adverse safety signals are explicitly reported in the reviewed abstracts. All mechanistic studies were in vitro; no human clinical safety data are described. PMID 24003726
Protocol
No community dose for Vilon on record yet.
All studies (12)
- PMID 32362097 Human observational
Dental disease / oral and maxillofacial pathology (bioregulatory therapy) - PMID 23486604 Mixed
Immunomodulation - PMID 24003726 Mixed
Geroprotection / anti-aging - PMID 32399807 Mixed
Geroprotection / anti-aging - PMID 33342107 Mixed
Geroprotection / anti-aging - PMID 35408963 Mixed
Immunomodulation - PMID 37782636 Mixed
Geroprotection / anti-aging - PMID 24423684 In vitro only
Genome functional regulation in hypertrophic cardiomyopathy - PMID 25826983 In vitro only
Regulation of CCL11 and HMGB1 gene expression (aging biomarkers) - PMID 29322736 In vitro only
Skin aging / fibroblast function - PMID 30791821 In vitro only
Neuronal differentiation of stem cells - PMID 37042594 In vitro only
Epigenetic modification / chromatin remodeling in aging
Frequently asked
What is Vilon and what is it used for?
Vilon is a synthetic dipeptide (Lys-Glu, also called the KE peptide) originally characterized by Prof. Khavinson and classified as a peptide bioregulator. It has been studied in vitro for immunomodulatory effects (PMID 23486604; PMID 35408963), geroprotective effects in aging stem cells (PMID 37782636; PMID 32399807), skin fibroblast function, and chromatin remodeling in aged lymphocytes. Clinical use as a geroprotector has been described in a review context, but most mechanistic data come from in vitro studies.
What dose of Vilon should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the available published abstracts only describe in vitro (cell culture) use of Vilon at 'nanomolar concentrations'; no human dosing protocols are reported in the reviewed literature.
How does Vilon work mechanistically?
According to molecular modeling data, the KE peptide can interact with specific DNA sequences (GCGG and GGGC) found in the promoters of SIRT1, PARP1, and PARP2 genes, suggesting direct regulation of gene expression. It has also been shown to induce chromatin remodeling (deheterochromatinization) in aged lymphocytes, modulate mitochondrial and ribosomal function in thymic cells, increase collagen I and sirtuin-6 in skin fibroblasts, and influence inflammatory signaling in monocyte/macrophage cell lines.
Is Vilon safe for human use?
The reviewed abstracts do not report specific safety, tolerability, or adverse event data for Vilon in humans. All mechanistic studies identified were conducted in vitro. Regulatory approval status is not stated in the reviewed literature. Please consult a licensed healthcare provider before use.
Can I stack Vilon with other peptides like Epitalon?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Vilon (KE) and Epitalon (AEDG) have been studied separately in aging cell models (PMID 33342107; PMID 37042594), and combinations of multiple peptides including KE have been evaluated for neuronal differentiation of stem cells, but no human stacking protocols or safety data for combinations are reported in the reviewed literature.
Where can I buy Vilon?
I don't recommend vendors or sources. Please consult a licensed provider.
What is the difference between Vilon and Epitalon?
Vilon is a dipeptide (Lys-Glu / KE), while Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly / AEDG). Both are classified as peptide bioregulators. Studies have shown they have different tissue-specific targets: KE peptide normalized mitochondrial and ribosomal function specifically in thymic cells, while AEDG showed similar effects in pineal gland cells. In chromatin studies, each peptide showed selective effects on distinct chromosome regions.
Does Vilon help with skin aging?
In vitro evidence suggests that KE dipeptide (Vilon) increased collagen type I expression area in 'old' skin fibroblast cultures by 83%, and increased sirtuin-6 expression in young and old fibroblasts by 1.6 and 2.6 times respectively. These are cell culture findings and do not directly demonstrate efficacy in humans.
Can Vilon treat my immune condition or autoimmune disease?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What has been studied: Vilon analogues affected T-cell differentiation markers in human and rat thymic cell cultures in vitro, and Vilon modulated inflammatory cytokine production in human monocyte/macrophage cell lines, but no clinical trials in autoimmune or immune conditions are described in the reviewed abstracts.
What genes does Vilon affect?
In human mesenchymal stem cell aging cultures, KE peptide modulated expression of IGF1, FOXO1, TERT, TNKS2, and NFκB genes at nanomolar concentrations. It also increased SIRT1 gene expression and protein synthesis by 6- and 8.2-fold in young MSCs, and reduced PARP1 and PARP2 gene expression and protein synthesis during MSC aging. Molecular modeling suggests interaction with GCGG and GGGC sequences found in promoters of these genes. It has also been proposed to regulate CCL11 and HMGB1 gene expression as aging biomarkers.